slotkoers
Korea S.E.
00:00:00 28-06-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
2.705
KRW
|
-2,35%
|
|
-1,99%
|
-28,44%
|
Fiscaal tijdperk: december |
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
586.015
|
233.826
|
175.143
|
77.366
|
Bedrijfswaarde
1 |
557.357
|
220.353
|
171.942
|
68.849
|
K/w-verhouding
|
-45,3
x
|
-8,61
x
|
-6,35
x
|
-2,58
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
1.831
x
|
532
x
|
442
x
|
111
x
|
Bedrijfswaarde/omzet
|
1.742
x
|
502
x
|
434
x
|
99
x
|
Bedrijfswaarde/EBITDA
|
-37,5
x
|
-20
x
|
-14,9
x
|
-5,66
x
|
Bedrijfswaarde/FCF
|
-32,5
x
|
-22,9
x
|
-22,4
x
|
-7,91
x
|
FCF Yield
|
-3,08%
|
-4,37%
|
-4,46%
|
-12,6%
|
Price to Book
|
9,29
x
|
5,24
x
|
7,15
x
|
3,78
x
|
Aantal aandelen (in duizenden)
|
14.250
|
14.426
|
14.545
|
20.467
|
Referentieprijs
2 |
41.125
|
16.208
|
12.042
|
3.780
|
Datum van publicatie
|
1/03/21
|
1/03/22
|
1/03/23
|
29/02/24
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
28,76
|
168,5
|
320
|
439,3
|
396
|
695,7
|
EBITDA
1 |
-8.247
|
-11.039
|
-14.858
|
-11.020
|
-11.538
|
-12.158
|
Bedrijfsresultaat (EBIT)
1 |
-8.569
|
-12.202
|
-16.089
|
-12.155
|
-12.579
|
-12.998
|
Operationele Marge
|
-29.792,04%
|
-7.241,7%
|
-5.027,71%
|
-2.767,18%
|
-3.176,64%
|
-1.868,29%
|
Resultaat voor belastingen (EBT)
1 |
-40.095
|
-42.554
|
-9.633
|
-22.519
|
-22.930
|
-23.961
|
Nettowinst (verlies)
1 |
-40.095
|
-42.554
|
-9.633
|
-22.519
|
-22.930
|
-23.961
|
Nettomarge
|
-139.404,45%
|
-25.254,54%
|
-3.010,19%
|
-5.126,47%
|
-5.790,66%
|
-3.444,23%
|
WPA
2 |
-22.149
|
-8.083
|
-908,2
|
-1.882
|
-1.897
|
-1.464
|
Free Cash Flow
1 |
18.468
|
-31.378
|
-17.164
|
-9.620
|
-7.677
|
-8.706
|
FCF-marge
|
64.210,31%
|
-18.621,91%
|
-5.363,72%
|
-2.190,04%
|
-1.938,6%
|
-1.251,4%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
1/03/19
|
29/02/20
|
1/03/21
|
1/03/22
|
1/03/23
|
29/02/24
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
15.282
|
16.880
|
28.658
|
13.473
|
3.201
|
8.518
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
18.468
|
-31.378
|
-17.164
|
-9.620
|
-7.677
|
-8.706
|
ROE (netto-inkomsten/eigen vermogen)
|
236%
|
869%
|
-22,3%
|
-41,8%
|
-66,3%
|
-107%
|
ROA (netto-inkomsten/totale activa)
|
-21,3%
|
-18%
|
-17,1%
|
-11,7%
|
-18,1%
|
-27,8%
|
Totale activa
1 |
188.279
|
236.845
|
56.198
|
193.171
|
126.968
|
86.164
|
Nettoactief per aandeel
2 |
-24.637
|
1.113
|
4.427
|
3.092
|
1.685
|
1.001
|
Cashflow per aandeel
2 |
6.302
|
293,0
|
5,440
|
200,0
|
476,0
|
220,0
|
Capex
1 |
968
|
9.273
|
1.480
|
676
|
505
|
236
|
Capex/omzet
|
3.366,11%
|
5.503,52%
|
462,36%
|
153,89%
|
127,49%
|
33,86%
|
Datum van publicatie
|
1/03/19
|
29/02/20
|
1/03/21
|
1/03/22
|
1/03/23
|
29/02/24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -28,44% | 40,18 mln. | | +15,20% | 121 mld. | | +19,67% | 113 mld. | | +17,99% | 26,02 mld. | | -23,86% | 19,39 mld. | | -19,03% | 15,91 mld. | | -20,90% | 15,09 mld. | | -46,14% | 15,06 mld. | | +63,85% | 14,93 mld. | | +4,49% | 13,85 mld. |
Biotherapeutische geneesmiddelen
|